[R01] Towards characterization of Epigenetic targets in Prostate Cancer
Ente: National Cancer Institute
Scadenza: 2030-06-30
Importo max: $350,285
Paese: US
Descrizione
Project Summary:
Prostate cancer (PCa) affects nearly 250,000 men in the United States annually, making it the
second leading cause of cancer-related deaths in men, with over 30,000 fatalities each year,
mainly due to metastatic castration-resistant prostate cancer (mCRPC). The androgen receptor
(AR) is a ligand-responsive transcription factor that drives terminal differentiation of the prostatic
luminal epithelia. However, AR gets hijacked upon transformation, and the cancer cells become
dependent on its activity. This dependency makes androgen/AR-targeted therapies common after
initial treatments like surgery or radiation. However, the disease often returns through various
mechanisms that restore AR-signaling, driving cancer progression. Despite advancements in
antiandrogen therapies, 20-40% of mCRPC patients show resistance to drugs like abiraterone
and enzalutamide, and many others develop resistance over time. A major challenge in treating
advanced PCa is its reliance on AR-driven oncogenic transcriptional program, which involves
multiple cofactors and chromatin proteins. Our long-term goal is to identify, characterize, and
therapeutically target these cofactors and chromatin-associated proteins in the context of AR
signaling in prostate cancer. We previously demonstrated that NSD2 overexpression is
associated with PCa progression. NSD2 (also named MMSET and WHSC1), a histone lysine
methyltransferase that catalyzes H3K36me2, is also implicated in the pathogenesis of multiple
myeloma and other hematological malignancies. Here, we identify NSD2 as a critical subunit of
AR enhanceosome (protein complex that assembles at enhancer regions) required for the
oncogenic AR transcriptional program. Our preliminary work indicates that the NSD2 interacts
with AR through its HMG-box domain and requires NSD2 catalytic activity to form the functional
AR enhanceosome. In Aim 1, we propose to gain deeper molecular mechanistic insights into how
NSD2 influences the chromatin landscape to facilitate the assembly of the AR enhanceosome
complex and enhance long-range enhancer-promoter looping for a hyperactive AR transcriptional
program in PCa cells. In Aim 2, we will evaluate the therapeutic potential of a novel first-in-class
small molecule inhibitor of NSD2, which also inhibits its paralog NSD1, in AR-driven prostate
cancer in vivo. This includes assessing the on-target activity and anti-tumor effects of the
compound in various prostate cancer models, including naïve and Enza-refractory CRPC, primary
explant, and organoid models. Together, these studies will provide critical new insights into how
epigenetic modifiers regulate oncogenic transcription factors to drive cancer progression.
Istituzione: UNIVERSITY OF TX MD ANDERSON CAN CTR
PI: Irfan Ahmed Asangani
Progetto: 7R01CA299870-03
Settori: National Cancer Institute
Vai al bando originale
Registrati gratis su Bandolo per trovare bandi compatibili con la tua azienda.